Neuroimaging endpoints for clinical trials in gliomas: the neuro-oncologist perspective.

IF 4.4 2区医学 Q1 CLINICAL NEUROLOGY

Current Opinion in Neurology Pub Date : 2025-08-08 DOI:10.1097/WCO.0000000000001419

Vihang Nakhate, Gilbert Youssef, Aleksandra B Lasica, Patrick Y Wen

{"title":"Neuroimaging endpoints for clinical trials in gliomas: the neuro-oncologist perspective.","authors":"Vihang Nakhate, Gilbert Youssef, Aleksandra B Lasica, Patrick Y Wen","doi":"10.1097/WCO.0000000000001419","DOIUrl":null,"url":null,"abstract":"Purpose of review: Accurate and reliable determination of tumor response and progression on neuroimaging is critical to identify effective therapies for glioma in clinical trials. In this article, we review response assessment criteria for adult glioma including their evolution over time, current recommendations, limitations, and future directions.Recent findings: Response Assessment in Neuro-Oncology (RANO) 2.0 delineates unified magnetic resonance imaging (MRI)-based criteria informed by patient data to evaluate endpoints of tumor response and tumor progression. The positron emission tomography (PET) RANO 1.0 criteria propose endpoints for tumor progression and response on amino acid PET imaging.Summary: The RANO 2.0 criteria provide standardized recommendations to assess tumor response and progression across adult glioma clinical trials regardless of tumor grade, contrast enhancement, molecular profile or treatment modality. Additional validation and exploratory studies can facilitate future refinements to the criteria and possible incorporation of novel neuroimaging endpoints. Advanced imaging modalities such as perfusion MRI and amino acid PET may help overcome some limitations of MRI-based response assessment.","PeriodicalId":11059,"journal":{"name":"Current Opinion in Neurology","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WCO.0000000000001419","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Accurate and reliable determination of tumor response and progression on neuroimaging is critical to identify effective therapies for glioma in clinical trials. In this article, we review response assessment criteria for adult glioma including their evolution over time, current recommendations, limitations, and future directions.

Recent findings: Response Assessment in Neuro-Oncology (RANO) 2.0 delineates unified magnetic resonance imaging (MRI)-based criteria informed by patient data to evaluate endpoints of tumor response and tumor progression. The positron emission tomography (PET) RANO 1.0 criteria propose endpoints for tumor progression and response on amino acid PET imaging.

Summary: The RANO 2.0 criteria provide standardized recommendations to assess tumor response and progression across adult glioma clinical trials regardless of tumor grade, contrast enhancement, molecular profile or treatment modality. Additional validation and exploratory studies can facilitate future refinements to the criteria and possible incorporation of novel neuroimaging endpoints. Advanced imaging modalities such as perfusion MRI and amino acid PET may help overcome some limitations of MRI-based response assessment.

查看原文本刊更多论文

神经胶质瘤临床试验的神经影像学终点：神经肿瘤学家的观点。

回顾目的：在临床试验中，准确可靠地确定肿瘤反应和神经影像学进展对于确定胶质瘤的有效治疗方法至关重要。在本文中，我们回顾了成人胶质瘤的反应评估标准，包括它们随时间的演变，目前的建议，局限性和未来的方向。近期发现：神经肿瘤学反应评估（RANO） 2.0描述了统一的基于磁共振成像（MRI）的标准，根据患者数据评估肿瘤反应和肿瘤进展的终点。正电子发射断层扫描（PET） RANO 1.0标准提出了肿瘤进展和氨基酸PET成像反应的终点。摘要：RANO 2.0标准为成人胶质瘤临床试验中评估肿瘤反应和进展提供了标准化的建议，而不考虑肿瘤分级、增强、分子谱或治疗方式。额外的验证和探索性研究可以促进未来对标准的改进，并可能纳入新的神经影像学终点。先进的成像方式，如灌注MRI和氨基酸PET可能有助于克服基于MRI的反应评估的一些局限性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Neurology 医学-临床神经学

CiteScore

8.60

自引率

0.00%

发文量

174

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Neurology is a highly regarded journal offering insightful editorials and on-the-mark invited reviews; covering key subjects such as cerebrovascular disease, developmental disorders, neuroimaging and demyelinating diseases. Published bimonthly, each issue of Current Opinion in Neurology introduces world renowned guest editors and internationally recognized academics within the neurology field, delivering a widespread selection of expert assessments on the latest developments from the most recent literature.